UC
PVLA

Unterberg Capital’s Palvella Therapeutics PVLA Stock Holding History

Unterberg Capital’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$308K Buy
+688
New +$299K 0.4% 18

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Unterberg Capital's PVLA Position: Q3 2018 in Review

Unterberg Capital opened a new position in Palvella Therapeutics (PVLA) in Q3 2018: 688 shares worth $308K. The stake represents 0.4% of the portfolio and ranks #18 among its holdings.

105 funds tracked by Wall St. Rank hold PVLA as of Q3 2018.

  • Unterberg Capital held 688 shares of Palvella Therapeutics worth $308K as of Q3 2018.
  • Palvella Therapeutics was a new Unterberg Capital position in Q3 2018.
  • Palvella Therapeutics made up 0.4% of Unterberg Capital's portfolio in Q3 2018, its #18 holding.
  • 105 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2018.

Based on Unterberg Capital's 13F filing for Q3 2018, filed 24 Oct 2018.